Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicinal cannabis in adolescents with Tourette Syndrome
NCT05184478Phase 2Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabis in Tourette syndrome (TS), sponsored by Murdoch Children's Research Institute. Primary endpoints: Rate of study participant recruitment at 2 years and Participant withdrawal rate at Day 176. Started May 2022; status: completed.
02
Drugs
cannabis
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT05184478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184478.